Testosterone therapy for menopausal women currently forces patients to navigate insurance denials, custom compounding pharmacies, and micro-dosed male gels because no female-specific product holds FDA approval, according to recent health reporting. As demand rises for treatments targeting low sexual desire and fatigue, the U.S. Food and Drug Administration convened a public workshop on Thursday to examine the evidence, safety, and research gaps surrounding hormone therapy.
FDA Convenes Public Workshop on Menopausal Hormone Access
The Food and Drug Administration convened a public workshop on Thursday to examine the clinical evidence, safety profiles, and research gaps surrounding testosterone therapy for menopausal women. Interest in the treatment has grown as more women seek relief for symptoms such as low sexual desire, fatigue, and reduced quality of life during menopause. Yet, the absence of an FDA-approved female product leaves physicians relying on off-label prescribing and compounded formulations.
Clinical Evidence and Off-Label Treatment Realities
According to medical practitioners, testosterone therapy is supported by current evidence-based guidelines for only one specific indication: hypoactive sexual desire disorder (HSDD), which involves persistently low sexual desire. Clinical evidence supporting its use for energy, mood, bone health, or sleep remains limited. Despite this, many patients are eager to try it for secondary benefits. Because no female-specific formulation exists, doctors must choose between custom compounding pharmacies and micro-dosed FDA-approved male gel packets that patients must measure out at home.
Did you know? Current medical guidelines support prescribing testosterone to women for only one official indication: hypoactive sexual desire disorder (HSDD). Clinical proof for energy or mood improvements is still limited, according to practicing physicians.
Administrative Hurdles and Financial Costs of Off-Label Prescriptions
Insurance providers routinely deny coverage for off-label testosterone therapy, creating financial and administrative hurdles for patients, according to Dr. Kudzai Dombo, a board-certified obstetrician-gynecologist, Menopause Society-certified practitioner, and prescribing physician at Alloy Health. Dombo recalled that when she was prescribed testosterone, her insurance denied coverage and her physician recommended a compounded cream to avoid administrative burdens. By using a discount coupon to pay out of pocket, Dombo found that a 10-month supply of male gel packets cost less than a single month of compounded cream.
Dosing male products also presents clinical challenges. Dombo mentioned a patient in her private practice who used a syringe to precisely measure out one-tenth of a male gel packet every day. Even after three months of consistent use, the patient’s hormone levels remained unchanged in follow-up bloodwork, and no relief from symptoms was experienced.
Rising Advocacy and the Future of Female Hormone Therapy
Federal regulators have been pushed to officially evaluate scientific evidence and standardized access for female testosterone therapy due to increasing advocacy from medical professionals and patients. Dombo believes grassroots advocacy from patients and clinicians is forcing regulatory action. “We’re not going to stop knocking on the door, because there are several of us who believe that women deserve to be able to have access to just what they need,” Dombo stated.
Frequently Asked Questions
Is any testosterone product FDA-approved for women?
No. Currently, no testosterone product is FDA-approved for women in the U.S., meaning physicians must rely on off-label prescribing, compounded formulations, or micro-dosed male gels.
What condition does medical evidence support treating with testosterone in women?
Testosterone therapy is supported by current evidence-based guidelines for only one indication: persistently low sexual desire, also known as hypoactive sexual desire disorder (HSDD).
Why do insurance companies deny testosterone coverage for women?
Because the therapy is prescribed off-label for female patients, insurance companies routinely deny coverage, forcing clinicians and patients to pay out of pocket or seek workarounds.
What is your experience with navigating menopause treatments and hormone therapy? Join the conversation by leaving a comment below, and subscribe to our health newsletter for the latest updates.